Alyeska Investment Group L.P. reduced its position in shares of Ralliant Corporation (NYSE:RAL - Free Report) by 12.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 561,561 shares of the company's stock after selling 82,850 shares during the period. Alyeska Investment Group L.P. owned approximately 0.51% of Ralliant worth $41,348,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in RAL. Allworth Financial LP lifted its position in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company's stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. Rothschild Investment LLC raised its position in shares of Ralliant by 98.1% during the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company's stock valued at $31,000 after buying an additional 303 shares in the last quarter. Keybank National Association OH raised its position in shares of Ralliant by 1.6% during the 4th quarter. Keybank National Association OH now owns 19,667 shares of the company's stock valued at $1,001,000 after buying an additional 305 shares in the last quarter. UMB Bank n.a. grew its position in Ralliant by 49.6% in the fourth quarter. UMB Bank n.a. now owns 983 shares of the company's stock worth $50,000 after acquiring an additional 326 shares in the last quarter. Finally, Maryland State Retirement & Pension System grew its position in Ralliant by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company's stock worth $1,117,000 after acquiring an additional 329 shares in the last quarter.
Insiders Place Their Bets
In other news, SVP Karen M. Bick sold 6,062 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the sale, the senior vice president directly owned 31,668 shares of the company's stock, valued at approximately $2,280,096. This represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the firm's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $71.79, for a total value of $928,675.44. Following the transaction, the chief executive officer owned 251,967 shares of the company's stock, valued at $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.42% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on RAL shares. Wall Street Zen lowered Ralliant from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Morgan Stanley raised their price objective on Ralliant from $68.00 to $85.00 and gave the company an "overweight" rating in a report on Tuesday, June 23rd. Barclays boosted their target price on Ralliant from $52.00 to $67.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 13th. Vertical Research downgraded shares of Ralliant from a "buy" rating to a "hold" rating and set a $65.00 price target on the stock. in a research note on Wednesday, May 27th. Finally, TD Cowen upped their price objective on shares of Ralliant from $70.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $75.70.
Check Out Our Latest Stock Report on Ralliant
Ralliant Price Performance
RAL opened at $61.65 on Monday. The stock has a fifty day simple moving average of $68.40 and a two-hundred day simple moving average of $56.53. The company has a market cap of $6.82 billion, a price-to-earnings ratio of -5.68, a price-to-earnings-growth ratio of 2.29 and a beta of 1.61. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $75.41.
Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Research analysts predict that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.
Ralliant Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant's payout ratio is -1.84%.
Ralliant Company Profile
(
Free Report)
Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ralliant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ralliant wasn't on the list.
While Ralliant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
